These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 15574759)

  • 1. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
    Al-Kuraya K; Schraml P; Torhorst J; Tapia C; Zaharieva B; Novotny H; Spichtin H; Maurer R; Mirlacher M; Köchli O; Zuber M; Dieterich H; Mross F; Wilber K; Simon R; Sauter G
    Cancer Res; 2004 Dec; 64(23):8534-40. PubMed ID: 15574759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations.
    Cuny M; Kramar A; Courjal F; Johannsdottir V; Iacopetta B; Fontaine H; Grenier J; Culine S; Theillet C
    Cancer Res; 2000 Feb; 60(4):1077-83. PubMed ID: 10706127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer.
    Choschzick M; Heilenkötter U; Lebeau A; Jaenicke F; Terracciano L; Bokemeyer C; Sauter G; Simon R
    Cancer Biomark; 2010-2011; 8(2):53-60. PubMed ID: 21896991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.
    Al-Kuraya K; Novotny H; Bavi P; Siraj AK; Uddin S; Ezzat A; Sanea NA; Al-Dayel F; Al-Mana H; Sheikh SS; Mirlacher M; Tapia C; Simon R; Sauter G; Terracciano L; Tornillo L
    J Clin Pathol; 2007 Jul; 60(7):768-72. PubMed ID: 16882699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade.
    Miura S; Nakashima M; Ito M; Kondo H; Meirmanov S; Hayashi T; Soda M; Matsuo T; Sekine I
    Cancer; 2008 May; 112(10):2143-51. PubMed ID: 18348306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: Possible role of host factors and survival bias.
    Suspitsin EN; Sokolenko AP; Togo AV; Lazareva YR; Turkevich EA; Matsko DE; Henrich KO; Borresen-Dale AL; Schwab M; Cornelisse CJ; Imyanitov EN
    Int J Cancer; 2007 Jan; 120(2):297-302. PubMed ID: 17066426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes.
    Moelans CB; de Weger RA; Monsuur HN; Vijzelaar R; van Diest PJ
    Mod Pathol; 2010 Jul; 23(7):1029-39. PubMed ID: 20473280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours.
    Courjal F; Cuny M; Rodriguez C; Louason G; Speiser P; Katsaros D; Tanner MM; Zeillinger R; Theillet C
    Br J Cancer; 1996 Dec; 74(12):1984-9. PubMed ID: 8980401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPFIA1 and CCND1 are frequently coamplified in breast cancer.
    Dancau AM; Wuth L; Waschow M; Holst F; Krohn A; Choschzick M; Terracciano L; Politis S; Kurtz S; Lebeau A; Friedrichs K; Wencke K; Monni O; Simon R
    Genes Chromosomes Cancer; 2010 Jan; 49(1):1-8. PubMed ID: 19787783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.
    Stahl P; Seeschaaf C; Lebok P; Kutup A; Bockhorn M; Izbicki JR; Bokemeyer C; Simon R; Sauter G; Marx AH
    BMC Gastroenterol; 2015 Feb; 15():7. PubMed ID: 25649416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
    Champème MH; Bièche I; Hacène K; Lidereau R
    Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma.
    Ortiz AB; Garcia D; Vicente Y; Palka M; Bellas C; Martin P
    PLoS One; 2017; 12(11):e0188068. PubMed ID: 29140993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 8p deletion is strongly linked to poor prognosis in breast cancer.
    Lebok P; Mittenzwei A; Kluth M; Özden C; Taskin B; Hussein K; Möller K; Hartmann A; Lebeau A; Witzel I; Mahner S; Wölber L; Jänicke F; Geist S; Paluchowski P; Wilke C; Heilenkötter U; Simon R; Sauter G; Terracciano L; Krech R; von der Assen A; Müller V; Burandt E
    Cancer Biol Ther; 2015; 16(7):1080-7. PubMed ID: 25961141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of CCND1 , C-MYC , and FGFR1 amplification using modified SYBR Green qPCR and FISH in breast cancer.
    Azarnezhad A; Tabrizi M; Javan F; Mehdipour P
    Turk J Med Sci; 2018 Aug; 48(4):759-767. PubMed ID: 30119151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene amplification in ductal carcinoma in situ of the breast.
    Burkhardt L; Grob TJ; Hermann I; Burandt E; Choschzick M; Jänicke F; Müller V; Bokemeyer C; Simon R; Sauter G; Wilczak W; Lebeau A
    Breast Cancer Res Treat; 2010 Oct; 123(3):757-65. PubMed ID: 20033484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.
    Kwak Y; Yun S; Nam SK; Seo AN; Lee KS; Shin E; Oh HK; Kim DW; Kang SB; Kim WH; Lee HS
    J Transl Med; 2017 Aug; 15(1):167. PubMed ID: 28764718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer.
    Zaharieva BM; Simon R; Diener PA; Ackermann D; Maurer R; Alund G; Knönagel H; Rist M; Wilber K; Hering F; Schönenberger A; Flury R; Jäger P; Fehr JL; Mihatsch MJ; Gasser T; Sauter G; Toncheva DI
    J Pathol; 2003 Dec; 201(4):603-8. PubMed ID: 14648664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer.
    Simon R; Struckmann K; Schraml P; Wagner U; Forster T; Moch H; Fijan A; Bruderer J; Wilber K; Mihatsch MJ; Gasser T; Sauter G
    Oncogene; 2002 Apr; 21(16):2476-83. PubMed ID: 11971182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
    Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
    Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.